Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20355702 | 0.90 | GRM2 (0.52) | GRM2TSHRHTTALDH1A1L3MBTL1 | |
| SCHEMBL14191672 | 0.79 | ALDH1A1 (0.56) | GRM2TSHRHTTALDH1A1L3MBTL1 | |
| SCHEMBL17809479 | 0.78 | GRM2 (0.49) | GRM2ALDH1A1KMT2A | |
| SCHEMBL31228892 | 0.78 | GRM2 (0.46) | GRM2HTTALDH1A1MEN1KMT2A | |
| SCHEMBL839843 | 0.78 | ALDH1A1 (0.41) | GRM2ALDH1A1 | |
| SCHEMBL17809483 | 0.78 | GRM2 (0.49) | GRM2ALDH1A1MEN1KMT2APKM | |
| SCHEMBL8355374 | 0.76 | GRM2 (0.50) | GRM2TSHRHTTALDH1A1L3MBTL1 | |
| SCHEMBL24640290 | 0.76 | HTR3A (0.46) | GRM2TSHRMEN1KMT2A | |
| SCHEMBL18034947 | 0.75 | GRM2 (0.53) | GRM2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL18781841 | 0.75 | GRM2 (0.43) | GRM2TSHRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2019-06-18 | — | — | US | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | GRM2 3161/4885TSHR 3397/4885HTT 504/4885 |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | GRM2 3824/4885TSHR 464/4885HTT 449/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | GRM2 2647/4885TSHR 2223/4885HTT 527/4885 |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | PRMT5, HDAC5, CDK15 | GRM2 2401/4885TSHR 3397/4885HTT 2216/4885 |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | GRM2 3161/4885TSHR 3397/4885HTT 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.